Echinocandins: Production and applications

T. Emri, László Majoros, Viktória Tóth, I. Pócsi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi. They have a unique mechanism of action; as non-competitive inhibitors of β-1,3-glucan synthase complex they target the fungal cell wall. Results of the structure-activity relationship experiments let us develop semisynthetic derivatives with improved properties. Three cyclic lipohiexapeptides (caspofungin, micafungin and anidulafungin) are currently approved for use in clinics. As they show good fungicidal (Candida spp.) or fungistatic (Aspergillus spp.) activity against the most important human pathogenic fungi including azole-resistant strains, they are an important addition to the antifungal armamentarium. Some evidence of acquired resistance against echinocandins has been detected among Candida glabrata strains in recent years, which enhanced the importance of data collected on the mechanism of acquired resistance developing against the echinocandins. In this review, we show the structural diversity of natural echinocandins, and we summarize the emerging data on their mode of action, biosynthesis and industrial production. Their clinical significance as well as the mechanism of natural and acquired resistance is also discussed.

Original languageEnglish
Pages (from-to)3267-3284
Number of pages18
JournalApplied Microbiology and Biotechnology
Volume97
Issue number8
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Echinocandins
caspofungin
anidulafungin
Fungi
Candida glabrata
Azoles
Ascomycota
Aspergillus
Structure-Activity Relationship
Candida
Innate Immunity
Cell Wall

Keywords

  • β-1,3-Glucan synthase
  • Echinocandin resistance
  • Natural echinocandins
  • Non-ribosomal peptide synthase
  • Paradoxical growth
  • Semisynthetic echinocandins

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Echinocandins : Production and applications. / Emri, T.; Majoros, László; Tóth, Viktória; Pócsi, I.

In: Applied Microbiology and Biotechnology, Vol. 97, No. 8, 04.2013, p. 3267-3284.

Research output: Contribution to journalArticle

Emri, T. ; Majoros, László ; Tóth, Viktória ; Pócsi, I. / Echinocandins : Production and applications. In: Applied Microbiology and Biotechnology. 2013 ; Vol. 97, No. 8. pp. 3267-3284.
@article{172d065fea4f4dd6b073d45682f845ed,
title = "Echinocandins: Production and applications",
abstract = "The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi. They have a unique mechanism of action; as non-competitive inhibitors of β-1,3-glucan synthase complex they target the fungal cell wall. Results of the structure-activity relationship experiments let us develop semisynthetic derivatives with improved properties. Three cyclic lipohiexapeptides (caspofungin, micafungin and anidulafungin) are currently approved for use in clinics. As they show good fungicidal (Candida spp.) or fungistatic (Aspergillus spp.) activity against the most important human pathogenic fungi including azole-resistant strains, they are an important addition to the antifungal armamentarium. Some evidence of acquired resistance against echinocandins has been detected among Candida glabrata strains in recent years, which enhanced the importance of data collected on the mechanism of acquired resistance developing against the echinocandins. In this review, we show the structural diversity of natural echinocandins, and we summarize the emerging data on their mode of action, biosynthesis and industrial production. Their clinical significance as well as the mechanism of natural and acquired resistance is also discussed.",
keywords = "β-1,3-Glucan synthase, Echinocandin resistance, Natural echinocandins, Non-ribosomal peptide synthase, Paradoxical growth, Semisynthetic echinocandins",
author = "T. Emri and L{\'a}szl{\'o} Majoros and Vikt{\'o}ria T{\'o}th and I. P{\'o}csi",
year = "2013",
month = "4",
doi = "10.1007/s00253-013-4761-9",
language = "English",
volume = "97",
pages = "3267--3284",
journal = "Applied Microbiology and Biotechnology",
issn = "0175-7598",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Echinocandins

T2 - Production and applications

AU - Emri, T.

AU - Majoros, László

AU - Tóth, Viktória

AU - Pócsi, I.

PY - 2013/4

Y1 - 2013/4

N2 - The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi. They have a unique mechanism of action; as non-competitive inhibitors of β-1,3-glucan synthase complex they target the fungal cell wall. Results of the structure-activity relationship experiments let us develop semisynthetic derivatives with improved properties. Three cyclic lipohiexapeptides (caspofungin, micafungin and anidulafungin) are currently approved for use in clinics. As they show good fungicidal (Candida spp.) or fungistatic (Aspergillus spp.) activity against the most important human pathogenic fungi including azole-resistant strains, they are an important addition to the antifungal armamentarium. Some evidence of acquired resistance against echinocandins has been detected among Candida glabrata strains in recent years, which enhanced the importance of data collected on the mechanism of acquired resistance developing against the echinocandins. In this review, we show the structural diversity of natural echinocandins, and we summarize the emerging data on their mode of action, biosynthesis and industrial production. Their clinical significance as well as the mechanism of natural and acquired resistance is also discussed.

AB - The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi. They have a unique mechanism of action; as non-competitive inhibitors of β-1,3-glucan synthase complex they target the fungal cell wall. Results of the structure-activity relationship experiments let us develop semisynthetic derivatives with improved properties. Three cyclic lipohiexapeptides (caspofungin, micafungin and anidulafungin) are currently approved for use in clinics. As they show good fungicidal (Candida spp.) or fungistatic (Aspergillus spp.) activity against the most important human pathogenic fungi including azole-resistant strains, they are an important addition to the antifungal armamentarium. Some evidence of acquired resistance against echinocandins has been detected among Candida glabrata strains in recent years, which enhanced the importance of data collected on the mechanism of acquired resistance developing against the echinocandins. In this review, we show the structural diversity of natural echinocandins, and we summarize the emerging data on their mode of action, biosynthesis and industrial production. Their clinical significance as well as the mechanism of natural and acquired resistance is also discussed.

KW - β-1,3-Glucan synthase

KW - Echinocandin resistance

KW - Natural echinocandins

KW - Non-ribosomal peptide synthase

KW - Paradoxical growth

KW - Semisynthetic echinocandins

UR - http://www.scopus.com/inward/record.url?scp=84876679185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876679185&partnerID=8YFLogxK

U2 - 10.1007/s00253-013-4761-9

DO - 10.1007/s00253-013-4761-9

M3 - Article

C2 - 23463246

AN - SCOPUS:84876679185

VL - 97

SP - 3267

EP - 3284

JO - Applied Microbiology and Biotechnology

JF - Applied Microbiology and Biotechnology

SN - 0175-7598

IS - 8

ER -